BMO Capital Markets Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

Replimune Group (NASDAQ:REPL) had its target price hoisted by BMO Capital Markets from $14.00 to $18.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other equities analysts have also issued reports on REPL. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a report on Friday. Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. Finally, JPMorgan Chase & Co. lifted their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $17.00.

Replimune Group Trading Down 11.2 %

Shares of REPL opened at $13.26 on Friday. The stock’s fifty day simple moving average is $11.59 and its 200-day simple moving average is $9.76. The firm has a market capitalization of $907.25 million, a PE ratio of -4.35 and a beta of 1.19. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, research analysts predict that Replimune Group will post -3.02 earnings per share for the current year.

Insider Activity

In related news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in REPL. Millennium Management LLC grew its position in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Braidwell LP increased its position in Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. State Street Corp lifted its stake in Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares during the last quarter. Baker BROS. Advisors LP boosted its position in Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after buying an additional 699,679 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.